# Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic

> **NCT00127829** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 66 (estimated)

## Conditions studied

- Tumors

## Interventions

- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT00127829
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** 2008-01
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2009-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00127829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00127829, "Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00127829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*